Niemann-Pick Type C Market Poised for Strong 14.8% CAGR Growth (2025–2034) | DelveInsight
The NPC market remains constrained by the scarcity of approved therapies and a substantial unmet medical need. Nonetheless, upcoming treatments, including Cyclo Therapeutics’ Trappsol Cyclo, Azafaros’ oral small-molecule nizubaglustat (AZ-3102), and the early-stage candidate Adrabetadex (VTS-270), combined with increasing disease awareness, are
